Email: cspc@cspc.cn
Media
News Center
Dec. 27
2023
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR IRINOTECAN LIPOSOME INJECTION TO U.S. FDA
Dec. 14
VOLUNTARY ANNOUNCEMENT - DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULPHATE ORALLY DISINTEGRATING TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Dec. 08
VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) INCLUDED FOR EMERGENCY USE IN CHINA
Dec. 01
VOLUNTARY ANNOUNCEMENT - SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Nov. 29
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE SOS1 INHIBITOR (SYH2038) OBTAINS CLINICAL TRIAL APPROVAL
Nov. 23
CSPC Signs Cooperation Agreement with AstraZeneca for Joint Confirmatory Research Targeting Lung Cancer
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
